Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.42 |
| ▸ | MAPT | P10636 | 5/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | IL2 | P60568 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | NSD2 | O96028 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.36 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11918912 | 0.80 | MAPT (0.46) | ALDH1A1MAPTSMN1; SMN2KMT2AKDM4E | |
| SCHEMBL15432258 | 0.79 | HPGD (0.49) | ALDH1A1MAPTSMN1; SMN2KMT2AIL2 | |
| SCHEMBL1043517 | 0.76 | KDM4C (0.46) | ALDH1A1MAPTKMT2AIL2NPC1 | |
| SCHEMBL4139383 | 0.74 | ALDH1A1 (0.55) | ALDH1A1KMT2AIL2NPC1 | |
| SCHEMBL2107971 | 0.73 | NAMPT (0.48) | IL2 | |
| SCHEMBL17655428 | 0.73 | SIRT3 (0.50) | ALDH1A1MAPTSMN1; SMN2KMT2AIL2 | |
| SCHEMBL21870351 | 0.70 | RAB9A (0.60) | MAPTSMN1; SMN2KMT2AKDM4ENPC1 | |
| SCHEMBL16303157 | 0.70 | MDM4 (0.46) | MAPTSMN1; SMN2NPC1LMNA | |
| SCHEMBL19151050 | 0.70 | ALDH1A1 (0.46) | ALDH1A1MAPTSMN1; SMN2KMT2AKDM4E | |
| SCHEMBL5455951 | 0.70 | IL2 (0.40) | ALDH1A1IL2NPC1LMNAIKBKE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070249620-A1 | Urea Derivative | SANKYO COMPANY, LIMITED (JP) | 2007-10-25 | — | — | US | disclosed |
| EP-1764360-A1 | UREA DERIVATIVE | Sankyo Company, Limited (JP) | 2007-03-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249620-A1 | Urea Derivative | UGP2, SLC14A1, DGAT1 | ALDH1A1 731/4885MAPT 758/4885SMN1; SMN2 4424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.